Pneumococcal conjugate vaccine GSK1024850A — Competitive Intelligence Brief

Pneumococcal conjugate vaccine GSK1024850A (Pneumococcal conjugate vaccine GSK1024850A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pneumococcal conjugate vaccine. Area: Immunology.

phase 3 Pneumococcal conjugate vaccine Immunology Biologic

Target snapshot

Pneumococcal conjugate vaccine GSK1024850A (Pneumococcal conjugate vaccine GSK1024850A) — GlaxoSmithKline. This pneumococcal conjugate vaccine stimulates the immune system to produce antibodies against multiple serotypes of Streptococcus pneumoniae by conjugating polysaccharide antigens to a protein carrier.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pneumococcal conjugate vaccine GSK1024850A TARGET	Pneumococcal conjugate vaccine GSK1024850A	GlaxoSmithKline	phase 3	Pneumococcal conjugate vaccine
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
GSK1024850A (SynflorixTM)	GSK1024850A (SynflorixTM)	GlaxoSmithKline	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
Streptococcus pneumoniae serotype 3	Streptococcus pneumoniae serotype 3	University of Oxford	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae serotype 3 capsular polysaccharide
Prevnar13	Prevnar13	GlaxoSmithKline	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide capsule (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
PCV10 full dose	PCV10 full dose	Epicentre	marketed	Pneumococcal conjugate vaccine
PCV13 alone	PCV13 alone	Korea University Guro Hospital	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide capsule (13 serotypes)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Pneumococcal conjugate vaccine class)

1. GlaxoSmithKline · 12 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
3. Korea University Guro Hospital · 1 drug in this class
4. Merck Sharp & Dohme LLC · 1 drug in this class
5. Papua New Guinea Institute of Medical Research · 1 drug in this class
6. Pfizer Inc. · 1 drug in this class
7. Sanofi · 1 drug in this class
8. University of Minnesota · 1 drug in this class
9. University of Oxford · 1 drug in this class
10. Vabiotech · 1 drug in this class